Progentos Therapeutics Appoints Andrew Miller, Ph.D. to Chairman of its Board of Directors October 2, 2024
Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases May 20, 2024
